AU2014368548B2 - Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features - Google Patents

Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features Download PDF

Info

Publication number
AU2014368548B2
AU2014368548B2 AU2014368548A AU2014368548A AU2014368548B2 AU 2014368548 B2 AU2014368548 B2 AU 2014368548B2 AU 2014368548 A AU2014368548 A AU 2014368548A AU 2014368548 A AU2014368548 A AU 2014368548A AU 2014368548 B2 AU2014368548 B2 AU 2014368548B2
Authority
AU
Australia
Prior art keywords
vortioxetine
activity
treatment
nalmefene
opioid antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014368548A
Other languages
English (en)
Other versions
AU2014368548A1 (en
Inventor
Connie Sanchez Morillo
Gennady N. SMAGIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52146489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014368548(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of AU2014368548A1 publication Critical patent/AU2014368548A1/en
Application granted granted Critical
Publication of AU2014368548B2 publication Critical patent/AU2014368548B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014368548A 2013-12-20 2014-12-18 Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features Ceased AU2014368548B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201300710 2013-12-20
DKPA201300710 2013-12-20
DKPA201400590 2014-10-16
DKPA201400590 2014-10-16
PCT/EP2014/078515 WO2015091833A1 (en) 2013-12-20 2014-12-18 Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features

Publications (2)

Publication Number Publication Date
AU2014368548A1 AU2014368548A1 (en) 2016-06-30
AU2014368548B2 true AU2014368548B2 (en) 2019-09-19

Family

ID=52146489

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014368548A Ceased AU2014368548B2 (en) 2013-12-20 2014-12-18 Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features

Country Status (14)

Country Link
US (1) US10376506B2 (enExample)
EP (1) EP3082815B1 (enExample)
JP (1) JP6448645B2 (enExample)
KR (1) KR20160093025A (enExample)
CN (1) CN105828821B (enExample)
AU (1) AU2014368548B2 (enExample)
CA (1) CA2933733A1 (enExample)
CL (1) CL2016001570A1 (enExample)
ES (1) ES2694352T3 (enExample)
IL (1) IL246253A0 (enExample)
MX (1) MX368870B (enExample)
RU (1) RU2679661C1 (enExample)
SG (1) SG11201604944PA (enExample)
WO (1) WO2015091833A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018003930A2 (pt) * 2016-07-01 2018-09-25 H Lundbeck As regimes de dosagem de vortioxetina para início rápido de efeito antidepressivo
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
JP7549576B2 (ja) 2018-11-06 2024-09-11 パーデュー、ファーマ、リミテッド、パートナーシップ オピオイドアンタゴニストを送達するための組成物及び方法
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
WO2023170550A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Polymorph forms of aticaprant for use in treating major depressive disorder
TW202400135A (zh) 2022-03-07 2024-01-01 美商健生醫藥公司 包含阿替卡普蘭之組成物
TW202547487A (zh) * 2024-03-18 2025-12-16 學校法人東京理科大學 失樂症的治療或預防用醫藥組成物

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817665A (en) * 1993-03-02 1998-10-06 John S. Nagle Composition and method of treating depression using naloxone or naltrexone in combination with a serotonin reuptake inhibitor
US20020091075A1 (en) * 2000-12-21 2002-07-11 Carlezon Wiliam A. Treatment of depression
US20030153590A1 (en) * 2001-08-14 2003-08-14 Oy Contral Pharma Ltd Method of treating alcoholism or alcohol abuse
US20030181475A1 (en) * 2002-03-20 2003-09-25 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
US20040242974A1 (en) * 2001-08-09 2004-12-02 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US20070179168A1 (en) * 2005-11-28 2007-08-02 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
US20070259939A1 (en) * 2006-05-04 2007-11-08 Accelerated Technologies Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
WO2014120936A2 (en) * 2013-01-30 2014-08-07 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
WO2014170351A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with mood disorder

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013740A (en) 1990-03-22 1991-05-07 Hillel Glover Method for treating emotional numbness and coma
US5028612A (en) 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CN101432011A (zh) * 2006-02-27 2009-05-13 亚历山大·米哈洛 通过诱导逆适应调节神经递质系统的方法
WO2008066916A1 (en) 2006-11-30 2008-06-05 The Mclean Hospital Corporation Methods for the treatment of mood disorders
DE502007002185D1 (de) * 2006-04-04 2010-01-14 Emodys Gmbh Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen
KR101627901B1 (ko) 2006-06-16 2016-06-13 하. 룬트벡 아크티에 셀스카브 인지기능 장애의 치료를 위한, 세로토닌 재흡수, 5-ht3 및 5-ht1a 활성이 조합된 화합물로서의 1-[2-(2,4-디메틸페닐술파닐)-페닐]피페라진
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
MY158251A (en) 2009-05-25 2016-09-30 H Lundbeck As Method for the preparation of nalmefene hydrochloride
WO2011020030A2 (en) * 2009-08-13 2011-02-17 The General Hospital Corporation Methods and compositions to prevent addiction
WO2011136376A1 (ja) 2010-04-30 2011-11-03 武田薬品工業株式会社 腸溶性錠剤
RS55777B1 (sr) 2010-11-05 2017-07-31 H Lundbeck As Postupak za proizvodnju naltreksona
CA2909506C (en) 2013-04-17 2021-04-20 H. Lundbeck A/S Nalmefene for treatment of patients with anxiety disorder

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817665A (en) * 1993-03-02 1998-10-06 John S. Nagle Composition and method of treating depression using naloxone or naltrexone in combination with a serotonin reuptake inhibitor
US20020091075A1 (en) * 2000-12-21 2002-07-11 Carlezon Wiliam A. Treatment of depression
US20040242974A1 (en) * 2001-08-09 2004-12-02 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US20030153590A1 (en) * 2001-08-14 2003-08-14 Oy Contral Pharma Ltd Method of treating alcoholism or alcohol abuse
US20030181475A1 (en) * 2002-03-20 2003-09-25 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
US20070179168A1 (en) * 2005-11-28 2007-08-02 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
US20070259939A1 (en) * 2006-05-04 2007-11-08 Accelerated Technologies Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
WO2014120936A2 (en) * 2013-01-30 2014-08-07 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
WO2014170351A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with mood disorder

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ADELL ALBERT, "Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety", I DRUGS: THE INVESTIGATIONAL DRUGS JOURNAL, CURRENT DRUGS LTD, GB, (2010-12), vol. 13, no. 12, pages 900 - 910 *

Also Published As

Publication number Publication date
KR20160093025A (ko) 2016-08-05
ES2694352T3 (es) 2018-12-20
CA2933733A1 (en) 2015-06-25
JP6448645B2 (ja) 2019-01-09
AU2014368548A1 (en) 2016-06-30
SG11201604944PA (en) 2016-07-28
CL2016001570A1 (es) 2016-12-09
MX2016007947A (es) 2016-09-09
EP3082815A1 (en) 2016-10-26
JP2016540030A (ja) 2016-12-22
US20160310488A1 (en) 2016-10-27
EP3082815B1 (en) 2018-10-03
CN105828821A (zh) 2016-08-03
US10376506B2 (en) 2019-08-13
MX368870B (es) 2019-10-21
RU2016123972A (ru) 2018-01-25
WO2015091833A1 (en) 2015-06-25
IL246253A0 (en) 2016-07-31
CN105828821B (zh) 2019-04-09
RU2679661C1 (ru) 2019-02-12

Similar Documents

Publication Publication Date Title
EP3082815B1 (en) Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
EP3552604B1 (en) Compositions for treating drug addiction and improving addiction-related behavior
WO2007005716A2 (en) Methods of treatment and compositions for use thereof
US10517841B1 (en) Compositions and methods for treating respiratory depression with fenfluramine
CN1527711A (zh) 用于药物治疗成瘾性物质或麻醉剂成瘾的活性成分组合物
TWI759579B (zh) 睡眠障礙治療及預防
H Rezvani et al. Novel medication targets for the treatment of alcoholism: preclinical studies
US20070053976A1 (en) Novel combination of drugs as antidepressant
BR102015011079A2 (pt) palmitoiletanolamida em forma não micronizada, em forma micronizada (pea-m), em forma ultramicronizada (pea-um) ou misturas das mesmas e composição farmacêutica ou veterinária
JPWO2008120562A1 (ja) 帯状疱疹後神経痛治療用錠剤および帯状疱疹後神経痛の治療方法
HK1229240A1 (en) Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
HK1229240B (en) Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
JP2012500248A (ja) 不安障害の治療
JP2015520145A (ja) 呼吸抑制の治療
EP1942891B1 (en) Novel combination of drugs as antidepressant
ES2975138T3 (es) Uso de 2-fenil-6-(1H-imidazol-1-il) quinazolina para la prevención del abuso y de los efectos secundarios de al menos un opioide
CA2909504C (en) Nalmefene for treatment of patients with mood disorder
US20110046173A1 (en) Combination analgesic opioid pain therapy
WO2024194263A1 (en) Serotonin 5ht2a receptor antagonist for use in treating side effects resulting form mu opioid receptor agonist overdose
KR20190120212A (ko) 알코올 사용 장해의 치료약
JPWO2008102859A1 (ja) 不安障害の予防および／または治療薬
JPWO2004078177A1 (ja) 薬物・物質依存治療薬

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired